Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118900774 | 11890077 | 4 | F | 20151011 | 20160825 | 20160105 | 20160830 | EXP | JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-074999 | BRISTOL MYERS SQUIBB | 55.06 | YR | M | Y | 73.60000 | KG | 20160830 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118900774 | 11890077 | 1 | PS | ELIQUIS | APIXABAN | 1 | Oral | 5 MG, BID | 110 | MG | Y | 202155 | 5 | MG | FILM-COATED TABLET | BID | |||
| 118900774 | 11890077 | 2 | SS | PLAVIX | CLOPIDOGREL BISULFATE | 1 | Unknown | 75 MG, QD | 150 | MG | Y | 0 | 75 | MG | TABLET | QD | |||
| 118900774 | 11890077 | 3 | SS | BAYASPIRIN | ASPIRIN | 1 | Oral | 100 MG, QD | 400 | MG | Y | 0 | 100 | MG | TABLET | QD | |||
| 118900774 | 11890077 | 4 | SS | EFIENT | PRASUGREL HYDROCHLORIDE | 1 | Oral | 3.75 MG, QD | 8 | MG | Y | 0 | 3.75 | MG | TABLET | QD | |||
| 118900774 | 11890077 | 5 | C | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 20 MG, QD | U | 0 | 20 | MG | CAPSULE | QD | |||||
| 118900774 | 11890077 | 6 | C | ARTIST | CARVEDILOL | 1 | Oral | 10 MG, QD | 65 | MG | U | 0 | 10 | MG | QD | ||||
| 118900774 | 11890077 | 7 | C | ARTIST | CARVEDILOL | 1 | Oral | 2.5 MG, QD | 65 | MG | U | 0 | 2.5 | MG | QD | ||||
| 118900774 | 11890077 | 8 | C | RENIVACE | ENALAPRIL | 1 | Oral | 2.5 MG, QD | U | 0 | 2.5 | MG | QD | ||||||
| 118900774 | 11890077 | 9 | C | MAINTATE | BISOPROLOL FUMARATE | 1 | Oral | 5 MG, QD | U | 0 | 5 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 118900774 | 11890077 | 1 | Thrombosis prophylaxis |
| 118900774 | 11890077 | 2 | Myocardial ischaemia |
| 118900774 | 11890077 | 3 | Myocardial ischaemia |
| 118900774 | 11890077 | 4 | Myocardial ischaemia |
| 118900774 | 11890077 | 5 | Product used for unknown indication |
| 118900774 | 11890077 | 6 | Product used for unknown indication |
| 118900774 | 11890077 | 8 | Product used for unknown indication |
| 118900774 | 11890077 | 9 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 118900774 | 11890077 | HO |
| 118900774 | 11890077 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 118900774 | 11890077 | Contraindicated product administered | |
| 118900774 | 11890077 | Gastrointestinal endoscopic therapy | |
| 118900774 | 11890077 | Gastrointestinal haemorrhage | |
| 118900774 | 11890077 | Gastrointestinal ulcer | |
| 118900774 | 11890077 | Polyp |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 118900774 | 11890077 | 1 | 20151001 | 20151013 | 0 | |
| 118900774 | 11890077 | 2 | 20151010 | 20151013 | 0 | |
| 118900774 | 11890077 | 3 | 20151008 | 20151013 | 0 | |
| 118900774 | 11890077 | 4 | 20151008 | 20151009 | 0 | |
| 118900774 | 11890077 | 5 | 20151001 | 0 | ||
| 118900774 | 11890077 | 6 | 20151001 | 20151006 | 0 | |
| 118900774 | 11890077 | 7 | 20151005 | 20151006 | 0 | |
| 118900774 | 11890077 | 8 | 20151004 | 0 | ||
| 118900774 | 11890077 | 9 | 20151007 | 0 |